Objective-RAGE (receptor for advanced glycation end products) and EMMPRIN (extracellular matrix metalloproteinase inducer) are immune receptors for proinflammatory mediators. These receptors can also be found in a soluble form in the circulation. Soluble RAGE (sRAGE) has shown atheroprotective properties in animal studies, possibly by acting as a decoy receptor for its ligands. Whether sEMMPRIN (soluble EMMPRIN) has similar roles is unknown. We hypothesized that sRAGE and sEMMPRIN might be associated with vascular disease progression, incident coronary events, and mortality. Approach and Results-We measured baseline sRAGE and sEMMPRIN in 4612 cardiovascular disease-free individuals from the population-based Malmö Diet and Cancer cohort. Measurements of intima-media thickness in the common carotid artery were performed at inclusion and after a median of 16.5 years. sRAGE was negatively correlated with carotid intima-media thickness progression, independently of traditional cardiovascular risk factors, kidney function, and hsCRP (high sensitive C-reactive protein). Additionally, sRAGE was associated with decreased risk for major adverse coronary events (hazard ratio=0.90 [0.82-0.97]; P=0.009) and mortality (hazard ratio=0.93 [0.88-0.99]; P=0.011) during a follow-up period of 21 years. The relationship with mortality was independent of all considered potential confounders. We found no correlations between EMMPRIN, intima-media thickness progression, or prognosis. Conclusions-Individuals with high levels of circulating sRAGE have a slower rate of carotid artery disease progression and a better prognosis. Although its predictive value was too weak to promote sRAGE as a useful clinical biomarker in the population, the findings support further research into the potential anti-inflammatory and atheroprotective properties of this soluble receptor. Visual Overview-An online visual overview is available for this article. RAGE is present in most tissues and is involved in chronic inflammation and atherosclerosis. 9,10 Ligand binding to RAGE leads to production of proinflammatory cytokines, leukocyte activation, migration, and tissue infiltration. 6, 9 S100A9 also activates EMMPRIN (the extracellular matrix metalloproteinase inducer), also called CD147 or basigin.
C oronary artery disease (CAD) is the leading cause of death globally, responsible for 16% of all deaths worldwide. 1 Inflammation has a key role in the pathogenesis of atherosclerosis and CAD, mediating both atherogenesis and plaque destabilisation. 2 Circulating levels of inflammatory mediators have been linked to CAD progression and prognosis, and efforts have been made to find inflammatory biomarkers that can identify individuals at higher risk to develop CAD. 3 We have previously showed that a high level of the proinflammatory mediator S100A8/A9 in plasma is associated with higher neutrophil count, larger intima-media thickness (IMT) in the common carotid artery and higher incidence of coronary events and cardiovascular death. 4 S100A12, another member of the S100 protein family known as EN-RAGE (extracellular newly identified receptor for advanced glycation end products binding protein), has also shown strong independent associations with incident CAD and CAD mortality in a populationbased cohort. 5 However, the underlying mechanisms of these associations are still unclear. S100A8/A9 and S100A12 exert their effects through RAGE (receptor for advanced glycation end products) and TLR4 (Toll-like receptor 4). 6, 7 RAGE is a multiligand immune receptor that binds AGEs (advanced glycation end products), S100/calgranulin family proteins and HMGB-1 (high mobility group box-1). 8 It is expressed on several cell populations, including endothelial cells, smooth muscle cells, mononuclear phagocytes, and lymphocytes. 6, 9 RAGE is present in most tissues and is involved in chronic inflammation and atherosclerosis. 9, 10 Ligand binding to RAGE leads to production of proinflammatory cytokines, leukocyte activation, migration, and tissue infiltration. 6, 9 S100A9 also activates EMMPRIN (the extracellular matrix metalloproteinase inducer), also called CD147 or basigin. 11 EMMPRIN is expressed on leukocytes, platelets, cardiac fibroblasts, and endothelial cells 12 and is upregulated on activated T cells and monocytes during development to macrophages. 11, 13 S100A9 binding to EMMPRIN mediates leukocyte migration and secretion of proinflammatory cytokines. 11, 14 EMMPRIN is present in human atherosclerotic plaques, especially in a macrophage-rich environment. 11 While TLR4 is exclusively cell bound, RAGE and EMMPRIN also exist in a soluble form because of enzymatic cleavage from the cell surface or alternative splicing. 11, [15] [16] [17] The soluble forms of RAGE (sRAGE) and EMMPRIN (sEMMPRIN) can be detected and measured in the circulation. It has been suggested that sRAGE acts as a decoy receptor by binding RAGE ligands without activating the signaling pathways, thus having anti-inflammatory effects. 18, 19 Whether sEMMPRIN has similar protective properties against cardiovascular disease (CVD) is still unknown.
In this large population-based cohort study including 4612 individuals free from previous CVD, we examined the associations between sRAGE, sEMMPRIN, and the progression of IMT in the common carotid artery over a median follow-up period of 16.5 years. Additionally, we assessed the relationships between the soluble receptors and incident first-time major adverse coronary events (MACEs) and total mortality in the cohort. We hypothesized that high levels of the soluble receptors might associate with a positive prognosis because of their putative anti-inflammatory roles.
Subjects and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Study Population
We have used a subcohort of the prospective population-based Malmö Diet and Cancer study. The inclusion and exclusion flow chart is presented in Figure 1 . The Malmö Diet and Cancer study included subjects born between 1926 and 1945 living in Malmö, Sweden, recruited between March 1991 and September 1996 (n=28 449). 20 Between October 1991 and February 1994, a randomly selected subgroup of 6103 individuals participated in a study focusing on carotid artery disease epidemiology. 21 At baseline, the participants filled in a self-administered health questionnaire and went through an examination including clinical data and blood sample collection. Information about smoking status and current medication was collected from the questionnaire. Diabetes mellitus at baseline was defined as a self-report of a physician diagnosis or use of diabetes mellitus medication in the questionnaire or fasting whole blood glucose of >6.0 mmol/L. The biomarker analysis was successfully performed in 4742 subjects with a full set of clinical data and available fasting blood samples. Information on prevalent CVD was obtained through the National Hospital Discharge registry, the Stroke register of Malmö, and the regional myocardial infarction register. 22 Based on the information in the questionnaire and in the registers, we excluded from the current study a further 130 subjects with known CVD, characterized as previous acute myocardial infarction, stroke, coronary bypass graft surgery, or percutaneous coronary intervention. This left 4612 subjects for analysis, out of which 4581 had available data on ultrasonographic measurement of IMT in the right common carotid artery.
Between 2007 and 2012, the participants were invited to a follow-up examination of carotid artery IMT. Reexamination data are available for 3693 participants (Figure 1) . 23 The median time from baseline to IMT reexamination was 16.5 (15.5-17.8) years. All participants gave informed consent. The Ethics committee at Lund University approved the study, which was conducted in accordance with the Helsinki Declaration.
Outcomes
In a cross-sectional analysis, we studied the correlations between baseline sRAGE, sEMMPRIN, and carotid artery IMT measured at baseline. Prospectively, we examined the associations of baseline sRAGE and sEMMPRIN with carotid IMT at reexamination, total carotid IMT progression from baseline to reexamination, and the average carotid IMT progression per year during follow-up.
For incident clinical events, the participants were followed from baseline until the first incident MACE, emigration from Sweden or death, or until December 31, 2014. The primary outcome was MACE, defined as an acute coronary event, coronary bypass graft surgery, or percutaneous coronary intervention for stable angina pectoris. A coronary event was defined as a fatal or nonfatal myocardial infarction on the base of International Classification of Diseases, Ninth Revision (ICD-9) code 410 and International Classification of Diseases, Tenth Revision (ICD-10) code I21. The secondary outcome was total mortality. Information about the outcomes was obtained through the National Hospital Discharge Registry, the Regional myocardial infarction registry, and the Cause of Death Registry of Sweden. The median follow-up time to event was 21.5 (18.6-22.3) years for MACE and 21.7 (20.9-22.4) years for total mortality.
Biochemical Analyses
Analyses of baseline fasting whole blood glucose, plasma lipids, and creatinine were performed at the Department of Clinical Chemistry, Malmö University Hospital. hsCRP (High sensitive C-reactive protein) was assessed by using the Tina-quant CRP latex high sensitive assay (Roche Diagnostics). Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease formula. 24 A plasma aliquot was sent for analysis of sRAGE and sEMMPRIN, performed at the Science for Life Laboratory, Uppsala, Sweden, by the Proximity Extension Assay technique. 25 Oligonucleotide-labeled antibody pairs were allowed to bind to their respective targets in the plasma samples. By adding a DNA polymerase that induced extension and joining of the 2 oligonucleotides, a polymerase chain reaction template was formed and preamplified with universal primers. By using specific primers, the individual DNA sequence for each target protein was detected and quantified. The reactions were run on a microfluidic real-time quantitative polymerase chain reaction chip (96.96, Dynamic Array IFC, Fluidigm, Biomark) and read on a Biomark HD instrument. For RAGE, the between-run coefficient of variation was 11% and the within-run coefficient of variation was 9%, which is comparable with those obtained with commercially available ELISA kits. For EMMPRIN, the between-run coefficient of variation was 19% and the within-run coefficient of variation was 4%. Considering the large number of subjects included and the fact that cases and controls were randomly distributed among the different assay runs, the relatively high interassay variability of the sEMMPRIN analysis is unlikely to significantly impact the final results of the study, although we cannot exclude this possibility with certainty. Data analysis was performed by a preprocessing normalization procedure using Olink Wizard for GenEx (Multid Analyses, Sweden). All data for sRAGE and EMMPRIN are presented in arbitrary units (au).
Carotid Ultrasound
The carotid ultrasonographic examination has been described in detail earlier. 22 Briefly, the right common carotid artery was scanned in systole, at the top of the R-wave on EKG, with a B-mode ultrasonography system (Acuson XP/4 for the baseline examination and Acuson Sequoia for the follow-up examination) by certified sonographers. IMT was measured according to a standardized protocol as the mean wall thickness 1 cm proximal to the bifurcation. To minimize observer bias, each image was analyzed without knowledge of subject identification code.
Statistical Analyses
The differences in baseline characteristics between the different outcome were analyzed using the Mann-Whitney test for continuous variables and the χ 2 test for dichotomous variables. Associations between IMT data and biomarker levels were assessed by Pearson correlation tests and by multivariate linear regression analysis including 3 different models correcting for potential confounders. Model 1 was adjusted for age and sex; Model 2 additionally included body mass index (BMI), current smoking, diabetes mellitus, triglycerides, HDL (high-density lipoprotein), LDL (low-density lipoprotein), estimated glomerular filtration rate, systolic blood pressure, blood pressure medication, and statin medication; and Model 3 was adjusted for the same variables as Model 2 with the addition of hsCRP. Skewed variables were logarithmically transformed before analysis. The associations between biomarker levels and outcome were explored through a Kaplan-Meier survival analysis with log-rank test, followed by multivariate Cox proportional hazards analyses.
Results

Relationships Between sRAGE, sEMMPRIN, and Traditional Cardiovascular Risk Factors at Baseline
The baseline characteristics of the study population are presented in Table 1 . As expected, there was a greater proportion of men among the participants with incident MACE, and the individuals in this group were significantly older, had higher BMI, higher prevalence of dyslipidemia, diabetes mellitus, smoking, hypertension, and higher use of both lipid-lowering and blood pressure lowering medication. The MACE group also had significantly lower baseline sRAGE, while there was no difference in the sEMMPRIN concentration (Table 1) . We found similar differences in baseline characteristics between individuals that died during follow-up compared with survivors ( Table 1) .
The associations between biomarkers and cardiovascular risk factors are presented in Table 2 . We found no relationships with age and kidney function, and both biomarkers were higher in females. High sRAGE was significantly associated with low BMI, low diastolic blood pressure, higher LDL, and higher triglycerides (Table 2 ). In turn, high EMMPRIN was associated with high BMI, higher LDL, HDL and triglycerides, high systolic blood pressure, and ongoing blood pressure medication. Although sRAGE was not independently correlated with the presence of diabetes mellitus in this multivariate regression analysis, plasma sRAGE was significantly lower in patients with diabetes mellitus compared with diabetes mellitus-free controls (median [ In Spearman analyses of the correlations between the soluble receptors and established biomarkers of systemic inflammation, baseline sRAGE had a weak inverse correlation with total blood leukocyte counts (r=−0.087, P<0.001) and with plasma hsCRP (r=−0.080, P<0.001). In contrast, sEMMPRIN did not correlate with total leukocyte counts (r=0.006, ns) and was positively correlated with hsCRP (r=−0.082, P <0.001).
Inverse Correlation Between sRAGE and IMT Progression
In a Pearson correlation analysis, baseline sRAGE showed a weak but significant inverse correlation with IMT at reexamination, total IMT increase, and yearly IMT increase rate from baseline to follow-up (Table 3) . We confirmed these associations in multivariate linear regression analyses adjusted for age and sex (Table 3 , Model 1). The relationships remained significant after further adjustment for BMI, smoking, diabetes mellitus, blood lipids, estimated glomerular filtration rate, hypertension, statin use, and hsCRP ( 
sRAGE Is Inversely Associated With MACE and Total Mortality
MACE occurred in 546 of the participants during follow-up (12%) and 1205 died (26%). Acute fatal or nonfatal coronary events occurred in 428 of the 546 participants with MACE, and a further 118 cases underwent coronary bypass graft surgery or percutaneous coronary intervention revascularization without having suffered an acute event beforehand. Among the participants who died during follow-up, 341 deaths were because of CVD.
In a Kaplan-Meier survival analysis with log-rank test, participants with sRAGE in the highest tertile (tertile 3) had a significantly lower incidence of MACE compared with participants in the lowest tertile (Figure 2A) . Furthermore, the participants with sRAGE in tertile 3 also had a significantly lower incidence of total mortality ( Figure 2B ). There were no associations between sEMMPRIN tertiles and incident events (not shown).
We used multivariate Cox proportional hazard analyses adjusted for age and sex to prospectively investigate the associations between plasma levels of sRAGE and sEMMPRIN at baseline and the incidence of MACE and total mortality during follow-up. We found a significant negative association between sRAGE and incident MACE (Table 4 , Model 1). However, the significance was narrowly lost after further adjustment for BMI, smoking, diabetes mellitus, blood lipids, estimated glomerular filtration rate, hypertension, statin use, and hsCRP (Table 4 , Models 2 and 3). We also found a significant negative association between baseline sRAGE and total mortality, which was independent of all considered confounders (Table 4 , Models 1-3). No significant associations were seen between sEMMPRIN and the outcomes (Table  II in the online-only Data Supplement). In receiver operating curve prediction models for incident MACE, adding sRAGE to a model based on age and sex led to a marginal increase in C statistics (0.678 versus 0.665, ns).
Similarly, we found only a modest increase in C statistics for mortality prediction (0.725 versus 0.722, ns) in comparison with age and sex. Addition of sRAGE to a prediction model including all cardiovascular risk factors considered in Model 2 of the Cox regression analysis did not further increase the C statistics for either MACE or mortality. Baseline IMT, n=4612 and follow-up IMT, n=3693. Adjustment models: Model 1: age and sex. Model 2: age, sex, BMI, current smoking, diabetes mellitus, LDL, HDL, TG, eGFR, systolic blood pressure, blood pressure lowering medication, and statin medication. Model 3: age, sex, BMI, current smoking, diabetes mellitus, LDL, HDL, TG, eGFR, systolic blood pressure, blood pressure lowering medication, statin medication and hsCRP. BMI indicates body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; IMT, mean intima-media thickness in the common carotid artery; LDL, low-density lipoprotein; sRAGE, soluble receptor for advanced glycation end products; and TG, triglycerides. 
Discussion
To our knowledge, this is the largest prospective population-based cohort study to date to examine the associations between the soluble receptors sRAGE and sEMMPRIN, vascular disease progression, first-time coronary events, and mortality. We show that high sRAGE levels at baseline are associated with slower long-term carotid IMT progression, independently of traditional cardiovascular risk factors, kidney function, and hsCRP. Our results provide human data support to the findings of previous experimental studies demonstrating a direct antiatherogenic role of sRAGE.
26-30
We also found negative associations between baseline sRAGE, incident first-time coronary events, and mortality. Furthermore, we are the first to assess the prognostic value of sEMMPRIN in a population-based cohort. Interestingly, although EMMPRIN shares similar ligands with RAGE, with the potential to act in a similar manner as anti-inflammatory decoy receptor, we found no relationships between sEMMPRIN, CVD, and mortality. A large body of clinical evidence supports potential anti-inflammatory and atheroprotective roles of sRAGE. In cross-sectional studies, systemic sRAGE was negatively associated with coronary artery calcium score in the population-based Dallas Heart Study cohort 31 and with noncalcified coronary plaque burden in CAD patients. 32 In 100 patients with premature CAD and 40 CAD-free controls, plasma sRAGE was significantly lower in CAD patients and was an independent predictor of CAD severity. 33 In nondiabetic males, subjects with sRAGE levels within the lowest quartile had an almost 7× higher odds ratio for prevalent CAD compared with the highest quartile. 34 In this study, sRAGE was lowest in patients with concomitant CAD and peripheral artery disease. 35 Our data provide additional evidence for a link between sRAGE and vascular disease in the carotid territory. The accelerated IMT progression in individuals with low systemic sRAGE found in our study provides a putative explanation for previous findings linking lower sRAGE levels with an increased prevalence of subclinical cerebrovascular disease. 36 Interestingly, prospective studies investigating the value of sRAGE as a CVD risk biomarker have produced contradictory results, depending on the characteristics of the cohort. In 1201 CVD-free individuals with normal kidney function selected from the population-based ARIC study (Atherosclerosis Risk in Communities), high sRAGE was associated with a lower incidence of diabetes mellitus, coronary events, and mortality. 37 Additionally, sRAGE has also been found to be negatively related to all-cause mortality in an exploratory analysis of 3523 individuals from the Framingham Heart Study. 38 Together with our results, these data provide firm evidence of a potential protective role of sRAGE in the general population. In contrast, high sRAGE levels were associated with increased risk of cardiovascular events, cardiovascular death, and total mortality in patients with type 1 and type 2 diabetes Figure 2 . Kaplan-Meier diagrams of incident major adverse coronary events (MACEs) and total mortality during follow-up. Survival curves of incident MACE (A) and total mortality (B) in the entire cohort (n=4612), by tertiles of sRAGE (soluble receptor for advanced glycation end products) at baseline. The P values refer to the difference in incident MACE/mortality between the lowest tertile (T1) and the highest tertile (T3), calculated by a log-rank test. 39, 40 , and in patients with already established CVD. 41 Hypothetically, these data suggest that while steady-state sRAGE might elicit protective effects in the general population, the elevated levels of plasma sRAGE in patients with diabetes mellitus or CVD might reflect increased immune and inflammatory activation. Future studies including differential analyses of secreted versus cell-cleaved sRAGE are required to probe this hypothesis. 42 A potential explanation for the putative atheroprotective effects of sRAGE has been provided by findings showing that individuals with low plasma sRAGE have a dysfunctional endothelium. 43 Here, we show that subjects with low plasma sRAGE have a higher systemic inflammatory state, characterized by elevated circulating white blood cells and hsCRP. Similar inverse associations have been described between sRAGE and the proinflammatory alarmin S100A12 (EN-RAGE). 44 In patients with diabetes mellitus, low sRAGE in plasma was strongly associated with a poor glycemic control and with increased Framingham risk score for incident CVD. 44 Similarly, circulating sRAGE was significantly lower in patients with type 1 diabetes mellitus compared with nondiabetic subjects and was inversely associated with the prevalence of diabetic vascular complications. 45 In line with these studies, we have also found significantly lower sRAGE concentration in subjects with diabetes mellitus compared with subjects without diabetes mellitus at baseline. Data derived from mechanistic mouse studies support direct antiatherogenic, anti-inflammatory, and vasculoprotective effects of sRAGE, rather than mere bystander associations. sRAGE treatment reduced atherosclerosis progression in diabetic mice independently of glycemia and lipids 26, 27 and reduced vascular medial calcification in mice with chronic kidney disease. 28 Additionally, administration of sRAGE in diabetic rats rapidly reversed the vascular hyperpermeability and the AGE-induced endothelial dysfunction, 29 and sRAGE treatment has also been shown to reduce neointimal expansion after vascular injury. 30 Interestingly, we did not find any correlations between sEMMPRIN and IMT progression, MACE or mortality. S100A9, Cyclophilin A, and Cyclophilin B binding to EMMPRIN lead to monocyte recruitment, monocyte and platelet activation and secretion of proinflammatory cytokines, and EMMPRIN has been found to be expressed in mouse and human atherosclerotic plaques. 11 Moreover, sEMMPRIN is thought to be involved in the pathogenesis of myocardial infarction. 11 Thus, EMMPRIN might have an important role in CVD, but our results do not support a predictive role for the soluble form of the receptor for incident CAD and mortality in the general population.
Study Limitations
Our study has some important limitations that need to be considered. First, this association study cannot demonstrate causality of the relationship between sRAGE, IMT progression, and outcome. However, as discussed above, our results support and extend previous findings in both human and animal studies, and the protective properties of sRAGE in CVD have earlier been demonstrated in experimental settings. Secondly, as sRAGE and sEMMPRIN were expressed in arbitrary units by our analysis method, we are not able to determine concrete cutoff values for sRAGE as predictive biomarker and cannot compare the absolute plasma concentrations found in our cohort with those of other studies. Third, as we do not have detailed clinical data and plasma samples available at carotid IMT follow-up and at the time of the incident clinical events, it is unknown how changes in cardiovascular risk profile and medication during follow-up might have impacted plasma levels of the biomarkers and their relationships with the outcomes.
Conclusions and Clinical Perspective
In a large population-based cohort study, we demonstrate that high plasma sRAGE levels are prospectively associated with lower IMT progression over a 16.5-year period and with reduced risk of MACE and mortality in middle-aged subjects without previously known CVD. In contrast to MACE, the relationship with mortality was independent of traditional cardiovascular risk factors and hsCRP, suggesting that sRAGE might have a broader protective role in human disease not exclusively related to CAD. As discussed, animal studies have shown that sRAGE has anti-inflammatory and antiatherosclerotic properties, possibly acting as a scavenger receptor for proinflammatory RAGE ligands. Our human data provide further support for future studies aiming to develop sRAGE-based treatments for various cardiovascular entities. From a clinical point of view, mounting evidence from large population-based cohorts, including the present study, reveal associations between high plasma sRAGE and a good prognosis. However, the biomarker value of sRAGE in this context appears to be limited, as plasma sRAGE did not provide additional predictive information on top of age, sex and traditional cardiovascular risk factors.
